Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARCC4 |
Synonyms | |
Therapy Description |
ARCC4 is a proteolysis targeting chimera (PROTAC) targeting the androgen receptor (AR), which potentially induces AR degradation and inhibits tumor cell growth (PMID: 30271980). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARCC4 | ARCC-4|ARCC 4 | Hormone - Anti-androgens 54 | ARCC4 is a proteolysis targeting chimera (PROTAC) targeting the androgen receptor (AR), which potentially induces AR degradation and inhibits tumor cell growth (PMID: 30271980). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|